An open-label, multicenter phase II trial of SUNITINIB for patients with chemorefractory metastatic gastric cancer
M Moehler, J Hartmann, F Lordick, S Al-Batran, P Reimer, S Daum, T Trarbach, M Ebert, C Schimanski, P Galle · Zeitschrift für Gastroenterologie · 2010 · Heft 08
Bibliografische Angaben
Zusammenfassung
Aims: Since sunitinib is effective in metastatic renal cancer and GIST tumors, we evaluated tolerability and efficacy of sunitinib for the first time in highly pretreated caucasian patients (pts) with unresectable metastatic (met.) adenocarcinoma of stomach, esophagogastric junction or lower oesophagus. Methods: 52 caucasian pts were included after documented resistance to 5-FU, cisplatin, oxaliplatin, irinotecan and/or doxetacel. Inclusion criteria were KPS ≥70, measurable lesions and adequate organ functions. Sunitinib was given 50mg/day for 4 weeks with 2 weeks rest (4+2). In case of toxicity, dosage was redu…
